BMRN - BioMarin Pharmaceutical Inc. Stock Price and Quote

BMRN [NASD]

Index	NDX	P/E	126.49	EPS (ttm)	0.73	Insider Own	0.30%	Shs Outstand	186.04M	Perf Week	2.25%
Market Cap	17.55B	Forward P/E	30.37	EPS next Y	3.04	Insider Trans	-19.46%	Shs Float	184.48M	Perf Month	-14.80%
Income	141.60M	PEG	-	EPS next Q	0.19	Inst Own	-	Short Float / Ratio	3.95% / 4.74	Perf Quarter	-15.05%
Sales	2.10B	P/S	8.37	EPS this Y	301.40%	Inst Trans	2.03%	Short Interest	7.28M	Perf Half Y	5.23%
Book/sh	24.74	P/B	3.73	EPS next Y	199.51%	ROA	2.30%	Target Price	122.76	Perf Year	13.00%
Cash/sh	6.79	P/C	13.59	EPS next 5Y	-	ROE	3.10%	52W Range	70.73 - 117.77	Perf YTD	-10.83%
Dividend	-	P/FCF	319.69	EPS past 5Y	30.20%	ROI	2.50%	52W High	-21.64%	Beta	0.39
Dividend %	-	Quick Ratio	3.20	Sales past 5Y	9.80%	Gross Margin	76.90%	52W Low	30.48%	ATR	2.78
Employees	3082	Current Ratio	4.70	Sales Q/Q	19.50%	Oper. Margin	7.10%	RSI (14)	37.34	Volatility	3.27% 2.78%
Optionable	Yes	Debt/Eq	0.24	EPS Q/Q	99.60%	Profit Margin	6.80%	Rel Volume	0.81	Prev Close	92.34
Shortable	Yes	LT Debt/Eq	0.24	Earnings	Feb 27 AMC	Payout	0.00%	Avg Volume	1.54M	Price	92.29
Recom	2.00	SMA20	-4.39%	SMA50	-12.62%	SMA200	-1.70%	Volume	349,134	Change	-0.06%

Mar-21-23

Initiated

Bernstein

Underperform

$81

Feb-22-23

Downgrade

Oppenheimer

Outperform → Perform

Feb-21-23

Initiated

Citigroup

Neutral

$116

Jan-30-23

Initiated

BMO Capital Markets

Market Perform

$107

Jan-18-23

Initiated

Canaccord Genuity

Hold

$119

Oct-31-22

Upgrade

Oppenheimer

Perform → Outperform

$92 → $110

Jul-13-22

Initiated

Cantor Fitzgerald

Overweight

$110

Jun-13-22

Resumed

Wedbush

Neutral

$146 → $70

Apr-25-22

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$96 → $113

Nov-22-21

Upgrade

William Blair

Mkt Perform → Outperform

Show Previous Ratings

Mar-14-23 08:00AM	BioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Achondroplasia PR Newswire
Mar-09-23 11:14AM	Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More Zacks
Mar-08-23 11:54AM	BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies Zacks
11:40AM	After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use Benzinga
08:44AM	Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? Zacks
04:05PM	Loading…
Mar-07-23 04:05PM	FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5 PR Newswire
08:22AM	U.S. FDA extends review of BioMarin's bleeding disorder therapy Reuters
07:42AM	FDA now set to decide on BioMarins hemophilia drug by June 30 MarketWatch
Mar-06-23 07:28PM	BioMarin Provides Update on FDA Review of ROCTAVIAN (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A PR Newswire -6.82%
05:10PM	Why BioMarin Shares Are Plunging Today? Benzinga
04:56PM	BridgeBio Soars 52% And Breaks Out After Smashing Expectations In A Dwarfism Study Investor's Business Daily
04:03PM	BridgeBio Soars 61% And Breaks Out After Smashing Expectations In A Dwarfism Study Investor's Business Daily
10:38AM	BridgeBio Stock Surges on Positive Dwarfism Drug Data. Its Bad News for BioMarin. Barrons.com
09:24AM	BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study Investor's Business Daily
08:26AM	BioMarins stock falls after another companys dwarfism drug moves into Phase 3 clinical trials MarketWatch
07:35AM	Loading…
07:35AM	Is BioMarin Pharmaceutical (BMRN) an Attractive Investment? Insider Monkey
Mar-02-23 08:30AM	BioMarin to Participate in Three Investor Conferences in March PR Newswire
05:45AM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2022 Earnings Call Transcript Insider Monkey
Mar-01-23 05:26AM	BioMarin Pharmaceutical Full Year 2022 Earnings: EPS Beats Expectations Simply Wall St.
Feb-28-23 10:28AM	Q4 2022 Biomarin Pharmaceutical Inc Earnings Call Thomson Reuters StreetEvents
10:17AM	BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023 Benzinga
09:40AM	Analyst Report: BioMarin Pharmaceutical Inc. Morningstar Research
09:10AM	BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down Zacks
02:26AM	Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics Zacks
Feb-27-23 05:35PM	BioMarin Pharmaceutical (BMRN) Q4 Earnings Lag Estimates Zacks
04:03PM	BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business PR Newswire
08:20AM	Here's How BioMarin Stock Looks Ahead of Earnings TheStreet.com
Feb-20-23 10:00AM	BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Feb-14-23 08:30AM	BioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023 PR Newswire
07:10AM	3 Prime Healthcare Takeover Targets Motley Fool
08:00AM	Loading…
Feb-07-23 08:00AM	BioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4:30 p.m. ET PR Newswire
Feb-03-23 04:13PM	BMRN Stock An Example Of Stock Market Character Change Investor's Business Daily
09:44AM	BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? Simply Wall St.
Jan-30-23 01:16PM	BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst Benzinga
Jan-25-23 03:24AM	Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last? Zacks
Jan-23-23 10:03AM	3 Drug Stocks With Promising Pipelines for 2023 InvestorPlace
Jan-10-23 12:43PM	2 Top Biotech Stocks Defying the Bear Market Motley Fool
Jan-09-23 09:25AM	Deals, data kick off biotech's big JPM Week American City Business Journals
Jan-08-23 11:00AM	BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis PR Newswire
Jan-07-23 08:40AM	Earnings growth outpaced the 29% return delivered to BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders over the last year Simply Wall St.
Jan-04-23 11:10AM	BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA Zacks +6.27%
08:30AM	BioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CA PR Newswire
Jan-03-23 04:05PM	European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2 PR Newswire
08:20AM	Dow Jones Futures Rise To Start 2023; Tesla Falls On This Delivery Red Flag Investor's Business Daily
01:00AM	Dow Jones Futures Rise: The Red Flag In Tesla's Deliveries Investor's Business Daily
12:45AM	Dow Jones Futures: The Red Flag In Tesla's Deliveries Investor's Business Daily
Jan-02-23 09:57PM	Dow Jones Futures Kick Off 2023; The Red Flag In Tesla's Deliveries Investor's Business Daily
09:44PM	Dow Jones Futures Fall To Start 2023; The Big Red Flag In Tesla Deliveries Investor's Business Daily
06:18PM	Dow Jones Futures Rise Heading Into Stock Market 2023; The Big Red Flag In Tesla Deliveries Investor's Business Daily
06:12PM	Dow Jones Futures Rise Into Stock Market 2023; Tesla Deliveries Fall Short Again Investor's Business Daily
05:57PM	Dow Jones Futures Loom For Stock Market 2023; Tesla Deliveries Fall Short Again Investor's Business Daily
12:51PM	Stock Market 2023: What To Do After 'Stay Away' Year; Tesla Deliveries Hit 405,278, Falling Short Investor's Business Daily
Dec-23-22 10:09AM	Biotech Stock Finds Favor Among Mutual Fund Managers Investor's Business Daily
Dec-02-22 11:31AM	Why Is Horizon Therapeutics (HZNP) Up 38.3% Since Last Earnings Report? Zacks
Dec-01-22 11:31AM	Incyte (INCY) Up 3.3% Since Last Earnings Report: Can It Continue? Zacks
Nov-25-22 01:52PM	Biotech Stock BioMarin Scores Breakout After FDA Announcement Investor's Business Daily
11:31AM	Why Is BioMarin (BMRN) Up 14.1% Since Last Earnings Report? Zacks
Nov-24-22 11:25AM	BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing Zacks
Nov-23-22 04:14PM	The FDA Just Approved Its Most Expensive Drug Ever Sending UniQure Stock On A Warpath Investor's Business Daily +7.25%
01:40PM	Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate Benzinga
08:29AM	BioMarin Announces Advancements in FDA Review of ROCTAVIAN (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A PR Newswire
Nov-08-22 10:09AM	History points to a post-midterm rally: Oppenheimer suggests 3 stocks to ride the momentum TipRanks
Nov-07-22 04:30PM	BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program PR Newswire
Nov-03-22 08:30AM	BioMarin to Participate in Two Upcoming Investor Conferences PR Newswire
Oct-31-22 07:20PM	7 Undervalued Biotech Stocks to Buy Before They Boom InvestorPlace
Oct-27-22 06:27PM	Why BioMarin Pharmaceuticals Fell 6.9% on Thursday Motley Fool -6.92%
12:26PM	BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View Zacks
08:35AM	Biomarin Posts Lower Q3 Loss, But Lags Street Consensus, Reaffirms Revenue Outlook Benzinga
Oct-26-22 06:55PM	BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings Estimates Zacks
04:03PM	BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®) PR Newswire
Oct-24-22 12:10PM	Can BioMarin (BMRN) Keep the Earnings Surprise Streak Alive? Zacks
Oct-21-22 09:11AM	4 Biotech Stocks Set to Outpace Q3 Earnings Estimates Zacks
Oct-20-22 10:02AM	Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q3 Earnings Expected to Decline Zacks
Oct-19-22 12:02PM	AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem Zacks
11:42AM	Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly Zacks
Oct-13-22 12:51PM	BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance Zacks
09:53AM	One Rejected BioMarin's Hemophilia Gene Therapy Goes Under FDA Review Benzinga
Oct-12-22 04:05PM	FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A PR Newswire
09:55AM	Wall Street Analysts See a 31% Upside in BioMarin (BMRN): Can the Stock Really Move This High? Zacks
Oct-07-22 05:57PM	While waiting for FDA decision on hemophilia gene therapy, BioMarin to lay off 120 American City Business Journals
03:00PM	Should You Invest in BioMarin Pharmaceutical (BMRN)? Insider Monkey
12:31PM	BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency Zacks
10:49AM	BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company Benzinga
Oct-06-22 07:00PM	BioMarin Simplifies Organizational Structure to Increase Efficiency PR Newswire
Oct-04-22 08:30AM	BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET PR Newswire
Sep-30-22 01:24PM	BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy Zacks
Sep-29-22 04:04PM	BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA PR Newswire
Sep-15-22 04:22PM	Something Unusual Is Happening Right Now With Biotech Stocks Investor's Business Daily
09:11AM	Top 10 Stock Picks of Roberto Mignones Bridger Management Insider Monkey
08:31AM	BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report PR Newswire
Sep-12-22 12:50PM	BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial Benzinga
Sep-03-22 08:00AM	Neurocrine Leads 5 Stocks To Watch In Sickly Market Investor's Business Daily
Sep-02-22 11:32AM	Why Is BioMarin (BMRN) Down 2.3% Since Last Earnings Report? Zacks
Aug-25-22 12:18PM	BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU Zacks
Aug-24-22 04:36PM	First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN (valoctocogene roxaparvovec), Approved by European Commission (EC) PR Newswire
Aug-12-22 11:39AM	Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal Zacks
10:33AM	Roche (RHHBY) Influenza Drug Gets FDA Nod for Children Zacks
Aug-09-22 07:44AM	Heres Why ClearBridge Investments Sold its Position in BioMarin (BMRN) Insider Monkey
Aug-04-22 07:34AM	BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings Benzinga +5.18%
07:31AM	BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales Zacks

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 13	Option Exercise	67.81	8,000	542,480	495,856	Mar 14 07:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 13	Sale	90.45	8,000	723,600	487,856	Mar 14 07:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 10	Option Exercise	67.81	15,000	1,017,150	502,856	Mar 14 07:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 10	Sale	92.28	15,000	1,384,200	487,856	Mar 14 07:40 PM
Davis George Eric	EVP, Chief Legal Officer	Feb 24	Option Exercise	67.81	1,474	99,952	56,725	Feb 28 09:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 13	Option Exercise	67.81	6,000	406,860	326,324	Feb 14 08:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 13	Sale	109.15	6,000	654,900	320,324	Feb 14 08:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 10	Option Exercise	67.81	15,000	1,017,150	335,324	Feb 14 08:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 10	Sale	110.11	15,000	1,651,650	320,324	Feb 14 08:00 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Jan 25	Option Exercise	67.81	49,000	3,322,690	90,088	Jan 27 09:35 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Jan 25	Sale	115.70	49,000	5,669,134	41,088	Jan 27 09:35 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 17	Option Exercise	67.81	10,000	678,100	330,424	Jan 18 09:41 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 17	Sale	111.55	10,000	1,115,500	320,424	Jan 18 09:41 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 13	Option Exercise	67.81	10,000	678,100	330,424	Jan 18 09:41 PM
Mueller Brian	EVP, Chief Financial Officer	Jan 13	Option Exercise	63.10	2,500	157,750	30,246	Jan 17 09:57 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 13	Sale	112.25	10,000	1,122,500	320,424	Jan 18 09:41 PM
Mueller Brian	EVP, Chief Financial Officer	Jan 13	Sale	114.50	2,500	286,250	27,746	Jan 17 09:57 PM
Mueller Brian	EVP, Chief Financial Officer	Dec 13	Option Exercise	63.10	2,500	157,750	30,246	Dec 15 06:22 PM
Mueller Brian	EVP, Chief Financial Officer	Dec 13	Sale	107.50	2,500	268,750	27,746	Dec 15 06:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Dec 13	Sale	106.89	1,000	106,890	320,424	Dec 15 04:43 PM
Mueller Brian	EVP, Chief Financial Officer	Dec 02	Option Exercise	67.81	5,900	400,079	31,507	Dec 06 09:29 PM
Mueller Brian	EVP, Chief Financial Officer	Dec 02	Sale	104.50	7,001	731,604	27,746	Dec 06 09:29 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Dec 02	Sale	103.98	1,500	155,967	321,424	Dec 06 09:09 PM
Mueller Brian	EVP, Chief Financial Officer	Nov 23	Option Exercise	67.81	3,500	237,335	32,347	Nov 28 09:42 PM
Mueller Brian	EVP, Chief Financial Officer	Nov 23	Sale	98.73	5,379	531,092	28,847	Nov 28 09:42 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Nov 02	Sale	86.12	3,000	258,360	41,088	Nov 04 05:25 PM
Alles Mark J	Director	Oct 31	Buy	86.75	3,625	314,469	10,905	Nov 02 06:42 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Oct 31	Sale	86.55	1,500	129,825	322,824	Nov 01 08:38 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Oct 14	Sale	89.89	4,000	359,560	324,324	Oct 18 08:01 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Aug 15	Sale	95.21	3,000	285,630	328,324	Aug 16 07:36 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Aug 12	Sale	94.75	4,000	379,000	331,324	Aug 16 07:36 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Aug 11	Sale	95.62	3,000	286,860	44,088	Aug 12 07:07 PM
Davis George Eric	EVP, Chief Legal Officer	Aug 09	Option Exercise	67.81	47,526	3,222,738	102,777	Aug 11 09:01 PM
Davis George Eric	EVP, Chief Legal Officer	Aug 09	Sale	95.96	51,216	4,914,664	55,251	Aug 11 09:01 PM
Guyer Charles Greg	EVP, Chief Technical Officer	Aug 08	Sale	96.56	6,205	599,155	42,168	Aug 10 07:52 PM
Davis George Eric	EVP, Chief Legal Officer	Jul 08	Sale	90.00	7,398	665,820	58,941	Jul 11 07:46 PM
Mueller Brian	EVP, Chief Financial Officer	Jul 08	Sale	89.50	7,337	656,662	30,726	Jul 12 02:25 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	May 26	Sale	78.94	1,308	103,254	54,109	May 31 09:29 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 06	Option Exercise	37.46	20,000	749,200	355,324	May 09 09:29 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 06	Sale	81.00	20,000	1,620,000	335,324	May 09 09:29 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 05	Option Exercise	37.46	10,000	374,600	345,324	May 09 09:29 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 05	Sale	84.14	10,000	841,400	335,324	May 09 09:29 PM
Mueller Brian	EVP, Chief Financial Officer	May 04	Option Exercise	37.46	11,800	442,028	48,401	May 06 07:45 PM
Mueller Brian	EVP, Chief Financial Officer	May 04	Sale	84.50	11,800	997,100	38,639	May 06 07:45 PM
Davis George Eric	EVP, Chief Legal Officer	May 02	Option Exercise	37.46	15,347	574,899	81,686	May 04 12:01 PM
MEIER RICHARD A	Director	May 02	Option Exercise	37.46	8,500	318,410	107,892	May 04 12:21 PM
Davis George Eric	EVP, Chief Legal Officer	May 02	Sale	80.38	15,347	1,233,592	66,339	May 04 12:01 PM
MEIER RICHARD A	Director	May 02	Sale	82.09	3,878	318,345	104,014	May 04 12:21 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 29	Option Exercise	37.46	5,000	187,300	339,983	May 02 09:27 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 29	Sale	81.95	5,000	409,750	334,983	May 02 09:27 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 28	Option Exercise	37.46	20,000	749,200	354,983	May 02 09:27 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 28	Sale	83.79	20,000	1,675,800	334,983	May 02 09:27 PM
Davis George Eric	EVP, Chief Legal Officer	Apr 25	Option Exercise	37.46	2,669	99,981	65,998	Apr 27 08:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 18	Option Exercise	37.46	20,000	749,200	354,983	Apr 20 08:20 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 18	Sale	81.91	20,000	1,638,200	334,983	Apr 20 08:20 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 14	Option Exercise	37.46	10,000	374,600	344,983	Apr 18 09:46 PM
LAWLIS V BRYAN	Director	Apr 14	Option Exercise	37.46	4,250	159,205	28,220	Apr 18 08:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 14	Sale	83.66	10,000	836,600	334,983	Apr 18 09:46 PM
LAWLIS V BRYAN	Director	Apr 14	Sale	83.66	4,250	355,555	23,970	Apr 18 08:22 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Apr 13	Sale	82.47	1,180	97,315	55,077	Apr 14 07:54 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 30	Sale	79.56	1,381	109,872	56,257	Mar 31 09:28 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 29	Sale	79.43	1,618	128,518	57,638	Mar 31 09:28 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 23	Sale	81.78	6,129	501,230	59,256	Mar 24 08:49 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 22	Sale	81.00	2,073	167,913	65,385	Mar 24 08:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience